Neuronetics (NASDAQ:STIM – Get Free Report) and Artivion (NYSE:AORT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Neuronetics and Artivion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neuronetics | 1 | 0 | 1 | 0 | 2.00 |
| Artivion | 1 | 0 | 7 | 0 | 2.75 |
Neuronetics currently has a consensus price target of $3.00, indicating a potential upside of 70.45%. Artivion has a consensus price target of $44.17, indicating a potential upside of 82.98%. Given Artivion’s stronger consensus rating and higher possible upside, analysts clearly believe Artivion is more favorable than Neuronetics.
Insider & Institutional Ownership
Risk & Volatility
Neuronetics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Earnings and Valuation
This table compares Neuronetics and Artivion”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neuronetics | $149.16 million | 0.82 | -$39.00 million | ($0.54) | -3.26 |
| Artivion | $441.33 million | 2.65 | $9.77 million | $0.24 | 100.57 |
Artivion has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Neuronetics and Artivion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neuronetics | -24.48% | -139.83% | -27.13% |
| Artivion | 2.55% | 7.15% | 3.63% |
Summary
Artivion beats Neuronetics on 13 of the 14 factors compared between the two stocks.
About Neuronetics
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
About Artivion
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
